Yazar "Turgutalp, Kenan" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Adult minimal change disease in Turkey: The results of Turkish society of nephrology glomerular diseases working group
    (Oxford University Press, 2020) Yılmaz, Mürvet; Sipahioğlu, Murat; Dervişoğlu, Erkan; Aydemir, Nihal; Uzun, Sami; İstemihan, Zülal; Ünsal, Oktay; Tatar, Erhan; Berktaş, Hacı Bayram; Özdemir Kayalar, Arzu; Şumnu, Abdullah; Şahin, Gizem Kumru; Çetinkaya, Hakkı; Kazan, Sinan; Koçyiğit, İsmail; Gökalp, Cenk; Hasbal, Nuri Barış; Uçar, Ayşe Serra; Özelsancak, Rüya; Güven Taymez, Dilek; Yadigar, Serap; Alagöz, Selma; Aslan, Bilal Burçak; Yaylacı, Selçuk; Aydın, Zeki; Jabrayilov, Jabrayil; Turgutalp, Kenan; Dursun, Belda; Şahin, Garip
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Epidemiological features of primary glomerular disease in Turkey: A multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group
    (BioMed Central Ltd, 2020) Türkmen, Aydın; Şumnu, Abdullah; Cebeci, Egemen; Yazıcı, Halil; Eren, Necmi; Seyahi, Nurhan; Dilek, Kamil; Dede, Fatih; Derici, Ülver; Ünsal, Abdulkadir; Şahin, Garip; Sipahioğlu, Murat; Gök, Mahmut; Tatar, Erhan; Dursun, Belda; Sipahi, Savaş; Yılmaz, Mürvet; Süleymanlar, Gültekin; Ulu, Sena; Güngör, Özkan; Kutlay, Sim; Bicik Bahçebaşı, Zerrin; Şahin, İdris; Kurultak, İlhan; Türkmen, Kültigin; Yılmaz, Zülfikar; Turan Kazancıoğlu, Rümeyza; Çavdar, Caner; Candan, Ferhan; Aydın, Zeki; Oygar, Duriye Deren; Gül, Cuma Bülent; Arıcı, Mustafa; Paydaş, Saime; Güven Taymez, Dilek; Küçük, Mehmet; Trablus, Sinan; Turgutalp, Kenan; Koç, Leyla; Sezer, Siren; Duranay, Murat; Bardak, Simge; Altıntepe, Lütfullah; Arıkan, İzzet Hakkı; Azak, Alper; Odabaş, Ali Rıza; Manga Şahin, Gülizar; Öztürk, Savaş
    Background The largest data on the epidemiology of primary glomerular diseases (PGDs) are obtained from the databases of countries or centers. Here, we present the extended results of the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group. Methods Data of patients who underwent renal biopsy and received the diagnosis of PGD were recorded in the database prepared for the study. A total of 4399 patients from 47 centers were evaluated between May 2009 and May 2019. The data obtained at the time of kidney biopsy were analyzed. After the exclusion of patients without light microscopy and immunofluorescence microscopy findings, a total of 3875 patients were included in the study. Results The mean age was 41.5 +/- 14.9 years. 1690 patients were female (43.6%) and 2185 (56.3%) were male. Nephrotic syndrome was the most common biopsy indication (51.7%). This was followed by asymptomatic urinary abnormalities (18.3%) and nephritic syndrome (17.8%). The most common PGD was IgA nephropathy (25.7%) followed by membranous nephropathy (25.6%) and focal segmental glomerulosclerosis (21.9%). The mean total number of glomeruli per biopsy was 17 +/- 10. The mean baseline systolic blood pressure was 130 +/- 20 mmHg and diastolic blood pressure was 81 +/- 12 mmHg. The median proteinuria, serum creatinine, estimated GFR, and mean albumin values were 3300 (IQR: 1467-6307) mg/day, 1.0 (IQR: 0.7-1.6) mg/dL, 82.9 (IQR: 47.0-113.0) mL/min and 3.2 +/- 0.9 g/dL, respectively. Conclusions The distribution of PGDs in Turkey has become similar to that in other European countries. IgA nephropathy diagnosed via renal biopsy has become more prevalent compared to membranous nephropathy.
  • Küçük Resim Yok
    Öğe
    Immunosuppressive treatment results in patients with primary iga nephropathy in Türkiye: A nationwide study
    (Oxford University Press, 2023) Oruç, Ayşegül; Şumnu, Abdullah; Türkmen, Aydın; Baştürk, Taner; Cebeci, Egemen; Turgutalp, Kenan; Çetinkaya, Hakkı; Güllülül, Mustafa
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group
    (2024) Oruç, Ayşegül; Türkmen, Aydın; Baştürk, Taner; Cebeci, Egemen; Turgutalp, Kenan; Çetinkaya, Hakkı; Üzerk Kibar, Müge; Seyahi, Nurhan; Tatar, Erhan; Ergül, Metin; Derici, Ülver; Aylı, Mehmet Deniz; Pınar, Musa; Bakar, Betül; Kazancıoğlu, Rümeyza; Yıldız, Abdülmecit; Dirim, Ahmet Burak; Yılmaz, Zülfükar; Türkmen, Kültigin; Tunca, Onur; Koç, Mehmet; Kutlay, Sim; Micozkadıoğlu, Hasan; Azak, Alper; Boztepe, Burcu; Üstündağ, Sedat; Şafak Öztürk, Seda; Ünsal, Abdulkadir; Karadağ, Serhat; Şahin, Gülizar; Coşgun Yenigün, Ezgi; Eren, Necmi; Güllülü, Mustafa; Gürsu, Meltem; Öztürk, Savaş; Şumnu, Abdullah
    Background: Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. Method: The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3–218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Results: Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08–1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51–0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49–0.91, p = 0.009) were found to be significant regarding remission. Conclusion: CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.
  • Küçük Resim Yok
    Öğe
    The relationship between severity of interstitial fibrosis and anemia in patient with primary glomerulonephritis: The data from TSN-Gold working group
    (Oxford University Press, 2020) Cebeci, Egemen; Turgutalp, Kenan; Öztürk, Savaş; Özlük, Yasemin; Gökçay Bek, Sibel; Şumnu, Abdullah; Seyahi, Nurhan; Yavuz, Mahmut; Pişkinpaşa, Serhan Vahit; Akçay, Ömer Faruk; Sakacı, Tamer; Şahin, Garip; Tokgöz, Bülent; Manga Şahin, Gülizar; Bozacı, İlter; Dursun, Belda; Sipahi, Savaş; Özdemir Kayalar, Arzu; Süleymanlar, Gültekin; Ulu, Memnune Sena; Güzel, Fatma Betül; Kutlay, Sim; Parmaksız, Ergün; Köz, Süleyman; Kurultak, İlhan; Selçuk, Nedim Yılmaz; Yıldırım, Yaşar; Gürsu, Meltem; Çavdar, Caner; Timuçin, Meryem; Aydın, Zeki; Oygar, Deren; Kahvecioğlu, Serdar; Üzerk Kibar, Müge; Torun, Dilek; Güven Taymez, Dilek; Küçük, Mehmet; Demir, Serap; Koç, Leyla; Sezer, Siren; Duranay, Murat; Bardak, Simge; Altıntepe, Lüftullah; Koç, Mehmet; Azak, Alper; Odabaş, Ali Rıza; Yılmaz, Zülfikar; Paydaş, Saime
    [Abstract Not Available]